VIGIL NEUROSCIENCE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.75 USD | -5.82% |
|
-16.16% | -18.64% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 329K | Capitalization | 103M |
|---|---|---|---|---|---|
| Net income 2024 * | -96M | Net income 2025 * | -123M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 43.16M | Net cash position 2025 * | 178M | EV / Sales 2025 * | -227 x |
| P/E ratio 2024 * |
-1.27
x | P/E ratio 2025 * |
-1.18
x | Employees | 69 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.57% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vigil Neuroscience, Inc.
More recommendations
More press releases
| 1 day | -5.82% | ||
| 1 week | -16.16% | ||
| Current month | -19.35% | ||
| 1 month | -12.42% | ||
| 3 months | -6.46% | ||
| 6 months | -56.07% | ||
| Current year | -18.64% |
1 week
2.75
3.23
1 month
2.723.52
Current year
2.533.68
1 year
2.5311.11
3 years
2.1818.27
5 years
2.1818.27
10 years
2.1818.27
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 20-06-30 | |
| Director of Finance/CFO | 50 | 20-06-30 | |
Kelly Neelon
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 20-06-30 | |
Mary Thistle
BRD | Director/Board Member | 64 | 22-04-17 |
Cheryl Blanchard
BRD | Director/Board Member | 59 | 20-10-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +1.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 2.75 | -5.82% | 50,239 |
| 24-04-17 | 2.92 | -3.63% | 42,887 |
| 24-04-16 | 3.03 | -4.11% | 60,572 |
| 24-04-15 | 3.16 | -1.86% | 38,819 |
| 24-04-12 | 3.22 | -1.83% | 54,159 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
Vigil Neuroscience, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its lead clinical candidate, VGL101 (iluzanebart), is a fully human monoclonal antibody TREM2 agonist that is being studied in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. The Company is also developing VG-3927, its orally available small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimerâs disease in genetically defined subpopulations.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
2.75
USD
Average target price
16.75
USD
Spread / Average Target
+509.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.64% | 103M | |
| -1.82% | 41.35B | |
| +41.70% | 40.38B | |
| +2.56% | 39.05B | |
| -12.11% | 26.67B | |
| +3.09% | 24.07B | |
| -24.16% | 18.36B | |
| +22.12% | 11.6B | |
| -3.74% | 11.68B | |
| +7.75% | 11.15B |
- Stock Market
- Equities
- VIGL Stock
